Use of Wharton's jelly-derived mesenchymal stromal cells for the treatment of equine recurrent uveitis: a pilot study
DOI:
https://doi.org/10.22319/rmcp.v14i1.6273Keywords:
Wharton's Jelly, Mesenchymal Stromal Cells, Equine recurrent uveitis, TherapeuticsAbstract
Equine recurrent uveitis (ERU) is a disease that affects 2 to 25 % of equines worldwide, 56% of which go blind; therefore, it is considered the most common cause of blindness in horses. ERU is a spontaneous immune-mediated condition characterized by recurrent intraocular inflammatory events. Currently, there is no treatment for horses with this disease. Mesenchymal stromal cells (MSCs) derived from various tissues, such as Wharton's jelly (WJ), have demonstrated their ability to modulate the immune response by negatively regulating the inflammatory process. The objective of this pilot study was to evaluate the effect of using MSCs derived from WJ as a treatment for ERU. The WJ was obtained and processed according to previously described methodologies for obtaining EMF. The horses involved in this study received a dose of 5x106 MSCs in the subpalpebral area. The research evaluated the concentration of interleukins (IL: IL-1a, IL-2, IL-10, IFN-g, and TNFa) in tear samples obtained before treatment inoculation, 30 min after the inoculation, and 7 days post inoculation. No significant changes in IL concentration were observed suggesting a decrease in pro-inflammatory ILs. However, horses with ERU treated with MSCs exhibited a positive response to therapy, evidenced by a decrease in signs of ERU. The results obtained suggest that treatment of ERU with WJ-derived MSCs is a safe alternative with promising results.
Downloads
References
Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells. Cell Med 2012;4(1):1-11. doi: 10.3727/215517912X647217.
Martínez‐Montiel MDP, Gómez‐Gómez GJ, Flores AI. Therapy with stem cells in inflammatory bowel disease. World J Gastroenterol 2014;20:1211‐1227.
Carrade Holt DD, Wood JA, Granick JL, Walker NJ, Clark KC, Borjesson DL. Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source. Stem Cells Dev 2014;23:1258‐1265.
Le Blanc K, Davies LC. Mesenchymal stromal cells and the innate immune response. Immunol Lett 2015;168:140‐146.
Iacono E, Rossi B, Merlo B. Stem cells from foetal adnexa and fluid in domestic animals: an update on their features and clinical application. Reprod Dom Anim 2015; 50:353–64. doi: 10.1111/rda.12499.
Weiss ML, Troyer DL. Stem cells in the umbilical cord. Stem Cell Rev 2016;2:155–162.
Iacono E, Pascucci L, Rossi B, Bazzucchi C, Lanci A, Ceccoli M, et al. Ultrastructural characteristics and immune profile of equine MSCs from fetal adnexa. Reproduction 2017;154:509–519. doi: 10.1530/REP-17–0032.
Gilger BC, Hollingsworth SR. Diseases of the uvea, uveitis, and recurrent uveitis. In: Gilger BC, editor. Equine ophthalmology. Hoboken, NJ: John Wiley & Sons, Inc. 2016: 369–415. doi: 10.1002/9781119047919.ch8.
Gilger BC, Deeg C. Chapter 8‐Equine recurrent uveitis. Gilger BC editor. Equine Ophthalmology, 2nd ed. Saint Louis, MO: W.B. Saunders; 2011:317‐349.
Sauvage AC, Monclin SJ, Elansary M, Hansen P, Grauwels MF. Detection of intraocular Leptospira spp. by real-time polymerase chain reaction in horses with recurrent uveitis in Belgium. Equine Vet J 2019;51:299–303.
Deeg CA. Ocular immunology in equine recurrent uveitis. Vet Ophthalmol 2008;11(Suppl 1):61‐65.
Deeg CA, Ehrenhofer M, Thurau SR, Reese S, Wildner G, Kaspers B. Immunopathology of recurrent uveitis in spontaneously diseased horses. Exp Eye Res 2002;75:127‐133.
Gilger BC, Malok E, Cutter KV, Stewart T, Horohov DW, Allen JB. Characterization of T‐lymphocytes in the anterior uvea of eyes with chronic equine recurrent uveitis. Vet Immunol Immunopathol 1999;71:17‐28.
Gilger BC, Michau TM. Equine recurrent uveitis: new methods of management. Vet Clin North Am Equine Pract 2004;20:417–27. doi: 10.1016/j.cveq.2004.04.010.
Kol A, Walker NJ, Nordstrom M, Borjesson DL. Th17 pathway as a target for multipotent stromal cell therapy in dogs: Implications for translational research. PLoS One 2016;11:e0148568.
Arzi B, Mills-Ko E, Verstraete FJM, Kol A, Walker NJ, Badgley MR, et al. Therapeutic efficacy of fresh, autologous mesenchymal stem cells for severe refractory gingivostomatitis in cats. Stem Cells Transl Med 2016;5:75–86.
Holt DDC, Wood JA, Granick JL, Walker NJ, Clark KC, Borjesson DL. Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source. Stem Cells Dev 2014;23:1258–1265.
Stewart MC, Stewart AA. Mesenchymal stem cells: characteristics, sources, and mechanisms of action. Vet Clin North Am Equine Pract 2011;27(2):243-61. doi: 10.1016/j.cveq.2011.06.004.
Madrigal M, Rao KS, Riordan NH. A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. J Transl Med 2014;12:260.
Meirelles LS, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009;20(5-6):419-27. doi: 10.1016/j.cytogfr.2009.10.002.
Cequier A, Sanz C, Rodellar C, Barrachina L. The usefulness of mesenchymal stem cells beyond the musculoskeletal system in horses. Animals (Basel). 2021;11(4):931. doi:10.3390/ani11040931.
Malalana F, Stylianides A, McGowan C. Equine recurrent uveitis: Human and equine perspectives. Vet J 2015;206(1):222-9. doi: 10.1016/j.tvjl.2015.06.017.
Saldinger LK, Nelson SG, Bellone RR, Lassaline M, Mack M, Walker NJ, Borjesson DL. Horses with equine recurrent uveitis have an activated CD4+ T-cell phenotype that can be modulated by mesenchymal stem cells in vitro. Vet Ophthalmol 2020;23(1):160-170. doi: 10.1111/vop.12704.
Davis AB, Schnabel LV, Gilger BC. Subconjunctival bone marrow-derived mesenchymal stem cell therapy as a novel treatment alternative for equine immune-mediated keratitis: A case series. Vet Ophthalmol 2019;22(5):674-682. doi: 10.1111/vop.12641.
Jiang TS, Cai L, Ji WY, Hui YN, Wang YS, Hu D, Zhu J. Reconstruction of the corneal epithelium with induced marrow mesenchymal stem cells in rats. Mol Vis 2010;14;16:1304-16.
Dodi PL. Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management. Vet Med (Auckl) 2015;30;6:341-347. doi: 10.2147/VMRR.S66705.
Cejkova J, Trosan P, Cejka C, Lencova A, Zajicova A, Javorkova E, Kubinova S, Sykova E, Holan V. Suppression of alkali-induced oxidative injury in the cornea by mesenchymal stem cells growing on nanofiber scaffolds and transferred onto the damaged corneal surface. Exp Eye Res 2013;116:312-23. doi: 10.1016/j.exer.2013.10.002.
Marfe G, Massaro-Giordano M, Ranalli M, Cozzoli E, Di Stefano C, Malafoglia V, Polettini M, Gambacurta A. Blood derived stem cells: an ameliorative therapy in veterinary ophthalmology. J Cell Physiol 2012;227(3):1250-1256. doi: 10.1002/jcp.22953.
Kol A, Wood JA, Carrade HDD, Gillette JA, Bohannon-Worsley LK, Puchalski SM, et al. Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses. Stem Cell Res Ther 2015;6(1):73. doi: 10.1186/s13287-015-0050-0.
Zhang J, Huang X, Wang H, Liu X, Zhang T, Wang Y, Hu D. The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy. Stem Cell Res Ther 2015;6:234. doi: 10.1186/s13287-015-0240-9.
Downloads
Published
How to Cite
-
Abstract776
-
PDF (Español)280
-
PDF300
-
Texto completo (Español)572
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
